Cost Effectiveness and Optimal Outcomes in HF

Slides:

Advertisements

Similar presentations

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Advertisements

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Diabetic Dyslipidemia in Practice

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Clinical Trials in IBD.

NOACs for Cancer-Associated Thrombosis:

Rapid Diagnostics and Stewardship: Combating the Rise of Antimicrobial Resistance.

Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

A CASE CHALLENGE IN HFrEF:

Residual Paralysis Is More Common Than You Think

COPD Management.

Biomarkers in Heart Failure

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Addressing Disease Burden in Asthma

Follow-Up of the Patient After PE

Treating HFrEF: Challenges Faced

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

EHL Technologies in Hemophilia Care

Gene Therapy: Past, Present, and Future

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Real-World Evidence in VTE

Evaluating New Therapies in HF

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Using Heart Rate as a Biomarker in Clinical Practice.

Managing Polycythemia Vera in the Community Setting

Revisiting the Pharmacoeconomics of HF

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018

New Strategies to Reduce HF Readmissions

Optimizing Joint Health in Hemophilia

Challenges in LA SCCHN.

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Novel Concepts in the Management of RCC

Improving Overall Health

Improving Adherence to Antiplatelet Therapy After an ACS Event

Assessing the Burden of Hyperkalemia

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

2015 EASD In Review: CV Risk management in t2dm

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

HF-Related Hospitalization and Readmissions

Assessing the Burden of Hyperkalemia

The Nurse View: Spotlight on EGFR-Mutated NSCLC

PAH Pathways: What Do the Data Tell Us?”

Case Studies in Peanut Allergy Immunotherapy

Optimizing Treatment of Refractory Gout

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

The Nurse View.

My PAH Patient.

Top Tips in Evidence-Based Care for HFrEF

Expert Perspectives.

Key Data on Improving Outcomes in HF Patients

Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.

Presentation transcript:

Cost Effectiveness and Optimal Outcomes in HF

Content Overview

The Importance of Considering Cost Effectiveness

Epidemiology and Costs Associated With HF Care

Costs Accumulated During Hospitalization Eclipse All Other HF-Related Costs

Measuring Cost Effectiveness

Measuring Cost Effectiveness (cont)

New Therapies for HF

SOC vs Treatment With New Agents

Pure Heart Rate Reduction Through If Current Inhibition

Ivabradine SHIFT Study

Effect of Ivabradine on Outcomes

Hypothetical Cost Projections in 1 Year: 1-Million-Member Insurance Plan

SHIFT: Ivabradine Improves QoL in Patients With HF

Role of Heart Rate as a CV Risk Biomarker

PARADIGM-HF (Sacubitril/Valsartan) Results

Sacubitril/Valsartan Decreases Risk of Recurrent Hospitalizations for Worsening HF

Cost Effectiveness of Sacubitril/Valsartan

Cost Effectiveness of Sacubitril/ Valsartan (cont)

Challenging Conventional Wisdom…

Angioedema AEs During Randomized Treatment

Concluding Remarks

Abbreviations

Abbreviations (cont)